



ASX ANNOUNCEMENT

Lumos Successfully Completes Retail Component of Entitlement Offer and A\$10.0 million Equity Raising

MELBOURNE, Australia 8 October 2024 – Lumos Diagnostics Holdings Limited (ACN 630 476 970) (ASX: LDX) (**Lumos** or the **Company**) is pleased to announce the successful completion of the retail component of its Entitlement Offer (ASX Announcements: 4 September 2024) (**Retail Entitlement Offer**) which raised approximately A\$6.9 million.

The Retail Entitlement Offer took place in conjunction with a 1 for 1.82 pro rata accelerated non-renounceable entitlement offer (**Entitlement Offer**) of new fully paid ordinary shares (**New Shares**) to raise approximately A\$10.0 million. The institutional component of the Entitlement Offer successfully completed on 6 September 2024, raising approximately A\$3.1 million.

Commenting on the outcome, Lumos CEO and Managing Director, Doug Ward said, *“With the Retail Entitlement Offer successfully reaching its target amount of A\$6.9 million, the capital raise was fully subscribed, bringing the total amount raised under the Entitlement Offer to A\$10.0 million.*

We appreciate the strong backing from all those investors who participated in this capital raise, particularly Tenmile and Ryder Capital, who are aligned with our vision to address unmet needs in human health. These funds provide Lumos with solid backing to drive the growth of our business.

Achieving CLIA waiver status in the US for our FebriDx® point-of-care test is high on our list of objectives, and we are moving forward with this project, with the aim of completing the CLIA waiver study and FDA application ahead of the 2025 US flu season.”

The Retail Entitlement Offer provided eligible retail shareholders in the Company (**Eligible Retail Shareholders**) the opportunity to subscribe for 1 New Share for every 1.82 existing fully paid ordinary shares which they held as at 7:00pm (AEST) on Friday, 6 September 2024 at a price of A\$0.038 (3.8 cents) per New Share.

The Retail Entitlement Offer closed at 5:00pm (AEST) on Wednesday, 2 October 2024 with valid applications for entitlements received raising approximately A\$0.3 million. Bell Potter Securities Limited (**Bell Potter**) acted as lead manager to the Entitlement Offer and underwriter to the Retail Entitlement Offer up to a maximum aggregate amount of approximately A\$6.1 million (**Underwritten Amount**). Ryder Capital Limited and Tenmile Ventures Pty Ltd acted as sub-underwriters for the Underwritten Amount (**Sub-Underwriters**). The shortfall after the issue of New Shares from the Retail Entitlement Offer was allocated to the Sub-Underwriters (in their respective proportions) up to the Underwritten Amount.

The New Shares not taken up in accordance with the Entitlement Offer (including by the Sub-Underwriters), totalling approximately A\$0.5 million has been placed by the Company (in consultation with Bell Potter) to institutional investors who participated in the Institutional Entitlement Offer (other than the Sub-Underwriters).

The settlement date for New Shares to be issued under the Retail Entitlement Offer, including the Underwritten Amount, is Tuesday, 8 October 2024 and the issue of New Shares under the Retail Entitlement Offer is scheduled to occur on Wednesday, 9 October 2024, with those shares expecting to commence trading on the ASX on Thursday, 10 October 2024. New Shares issued under the Retail Entitlement Offer will rank equally in all respects with existing ordinary shares on issue with effect from the date of issue.

Eligible Retail Shareholders should confirm the actual number of New Shares issued to them before trading in such shares, and the sale by any Eligible Retail Shareholder of New Shares prior to receiving their holding statement is at their own risk.

The Board of Lumos wishes to thank all those investors who participated in the capital raise. The funds raised through this process are critical to driving Lumos' product and services opportunities and sets the company up for future growth.

This announcement is authorised for release by the Lumos Disclosure Committee.

###

About Lumos Diagnostics

Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Media Contacts:

Haley Chartres – Australia
H^CK Director
haley@hck.digital
+61 (0) 423 139 163

Investor Contact:

Jane Lowe
Managing Director, IR Department
ir@lumosdiagnostics.com
+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598

Important Notices

This announcement is issued by Lumos Diagnostics Holdings Limited. This announcement is not a prospectus or offering document under Australian law or under any other law. It is for information purposes only and does not constitute an offer, invitation, solicitation, advice or recommendation to subscribe for, retain or purchase any entitlements or securities in Lumos Diagnostics Holdings Limited in any jurisdiction. This letter does not constitute financial product advice and does not and will not form any part of any contract for the acquisition of Lumos Diagnostics Holdings Limited ordinary shares.

For personal use only